文献速递前列腺癌

监测活检无癌是主动监测中疾病重新分级的预后标志:Canary PASS研究结果

Role of Surveillance Biopsy with No Cancer as a Prognostic Marker for Reclassification: Results from the Canary Prostate Active Surveillance Study.
PubMed 文献 · Eur Urol · 2018-02-09

基于Canary PASS队列2008-2016年657例接受主动监测的前列腺癌患者,首次监测活检无癌者未来重新分级风险显著降低(HR=0.50,p=0.008)。第二次活检无癌同样与重新分级风险降低相关(HR=0.15,p=0.003),不受首次活检结果影响。

要点

  • 首次监测活检无癌者未来重新分级风险降低50%(HR=0.50,p=0.008)。
  • 较低PSA、较大前列腺体积和较低BMI亦与重新分级风险降低相关。

核心结论

  • 在PASS队列中,监测活检无癌证据的患者在主动监测中发生重新分级的可能性显著降低。

研究设计与样本

  • Canary前列腺主动监测研究(PASS)队列,纳入2008-2016年657例Gleason≤3+4且诊断时核心受累比<34%的患者。
  • 监测前列腺穿刺活检计划为诊断后12和24个月,之后每24个月一次。

主要发现

  • 首次监测活检:214例(32%)无癌,282例(43%)有癌但未重新分级,161例(25%)重新分级。
  • 未重新分级者中313例接受第二次活检:120例(38%)无癌,139例(44%)有癌但未重新分级,54例(17%)重新分级。
  • 多变量分析中,首次活检后未来重新分级降低的显著预测因素包括活检无癌(HR=0.50,p=0.008)、较低血清PSA、较大前列腺体积和较低BMI。
  • 第二次活检无癌同样与未来重新分级显著降低相关(HR=0.15,p=0.003),不受首次活检结果影响。

关键数值与推荐

  • 重新分级定义为Gleason分级升高和/或活检核心癌比例增至≥34%。
  • 活检结果分类为:无癌、有癌但未重新分级、重新分级。

临床怎么用

  • 监测活检无癌结果可用于调整主动监测方案,可能影响未来活检频率。

局限性

  • 主要局限性为长期随访患者数量相对较少。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Many patients who are on active surveillance (AS) for prostate cancer will have surveillance prostate needle biopsies (PNBs) without any cancer evident. OBJECTIVE: To define the association between negative surveillance PNBs and risk of reclassification on AS. DESIGN, SETTING, AND PARTICIPANTS: All men were enrolled in the Canary Prostate Active Surveillance Study (PASS) between 2008 and 2016. Men were included if they had Gleason ≤3+4 prostate cancer and <34% core involvement ratio at diagnosis. Men were prescribed surveillance PNBs at 12 and 24 mo after diagnosis and then every 24 mo. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Reclassification was defined as an increase in Gleason grade and/or an increase in the ratio of biopsy cores to cancer to ≥34%. PNB outcomes were defined as follows: (1) no cancer on biopsy, (2) cancer without reclassification, or (3) reclassification. Kaplan-Meier and Cox proportional hazard models were performed to assess the risk of reclassification. RESULTS AND LIMITATIONS: A total of 657 men met inclusion criteria. On first surveillance PNB, 214 (32%) had no cancer, 282 (43%) had cancer but no reclassification, and 161 (25%) reclassified. Among those who did not reclassify, 313 had a second PNB. On second PNB, 120 (38%) had no cancer, 139 (44%) had cancer but no reclassification, and 54 (17%) reclassified. In a multivariable analysis, significant predictors of decreased future reclassification after the first PNB were no cancer on PNB (hazard ratio [HR]=0.50, p=0.008), lower serum prostate-specific antigen, larger prostate size, and lower body mass index. A finding of no cancer on the second PNB was also associated with significantly decreased future reclassification in a multivariable analysis (HR=0.15, p=0.003), regardless of the first PNB result. The major limitation of this study is a relatively small number of patients with long-term follow-up. CONCLUSIONS: Men who have a surveillance PNB with no evidence of cancer are significantly less likely to reclassify on AS in the PASS cohort. These findings have implications for tailoring AS protocols. PATIENT SUMMARY: Men on active surveillance for prostate cancer who have a biopsy showing no cancer are at a decreased risk of having worse disease in the future. This may have an impact on how frequently biopsies are required to be performed in the future.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Kearns JT, Faino AV, Newcomb LF, et al. Role of Surveillance Biopsy with No Cancer as a Prognostic Marker for Reclassification: Results from the Canary Prostate Active Surveillance Study. Eur Urol. 2018. PMID: 29433973. doi:10.1016/j.eururo.2018.01.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。